Brief: Marker Therapeutics Announces Complete Response In First Lymphoma Patient Treated With MT-601 After Car T Relapse
11/09/2023 12:23
Marker Therapeutics Inc MRKR.O :
* MARKER THERAPEUTICS ANNOUNCES COMPLETE RESPONSE IN FIRST
LYMPHOMA PATIENT TREATED WITH MT-601 AFTER CAR T RELAPSE
Source text for Eikon: ID:nGNX21YHMW
Further company coverage: MRKR.O
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79